Clinical use of measurable residual disease in adult ALL: recommendations from a panel of US experts. Read more about Clinical use of measurable residual disease in adult ALL: recommendations from a panel of US experts.
Novel Composite Health Assessment Risk Model for Older Allogeneic Transplant Recipients: BMT-CTN 1704. Read more about Novel Composite Health Assessment Risk Model for Older Allogeneic Transplant Recipients: BMT-CTN 1704.
Identification of genomic biomarkers of disease progression and survival in primary CNS lymphoma. Read more about Identification of genomic biomarkers of disease progression and survival in primary CNS lymphoma.
Impact of prior inotuzumab ozogamicin treatment on brexucabtagene autoleucel outcomes in adults with B-cell ALL. Read more about Impact of prior inotuzumab ozogamicin treatment on brexucabtagene autoleucel outcomes in adults with B-cell ALL.
Effect of rabbit ATG PK on outcomes after TCR-αβ/CD19-depleted pediatric haploidentical HCT for hematologic malignancy. Read more about Effect of rabbit ATG PK on outcomes after TCR-αβ/CD19-depleted pediatric haploidentical HCT for hematologic malignancy.
Beat-AML 2024 ELN-refined risk stratification for older adults with newly diagnosed AML given lower-intensity therapy. Read more about Beat-AML 2024 ELN-refined risk stratification for older adults with newly diagnosed AML given lower-intensity therapy.
Association of busulfan exposure and outcomes after HCT for patients with an inborn error of immunity. Read more about Association of busulfan exposure and outcomes after HCT for patients with an inborn error of immunity.
CD4+ CAR T-cell exhaustion associated with early relapse of multiple myeloma after BCMA CAR T-cell therapy. Read more about CD4+ CAR T-cell exhaustion associated with early relapse of multiple myeloma after BCMA CAR T-cell therapy.
Prognostic impact of cooccurring mutations in FLT3-ITD pediatric acute myeloid leukemia. Read more about Prognostic impact of cooccurring mutations in FLT3-ITD pediatric acute myeloid leukemia.
Real-world treatment patterns and outcomes in patients with primary hemophagocytic lymphohistiocytosis treated with emapalumab. Read more about Real-world treatment patterns and outcomes in patients with primary hemophagocytic lymphohistiocytosis treated with emapalumab.
